Can We Talk: Strategies to Communicate Long-Acting Injectables (LAIs) as an Effective Treatment Option for Bipolar I DisorderPremiere Date: Thursday, November 19, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, November 30, 2022
Note: Credit Is No Longer Available
|Roger S. McIntyre, MD, FRCPC
University of Toronto
University Health Network
Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA)
Clinical Professor, Department of Psychiatry and Neurosciences
University of California School of Medicine
Bipolar I disorder (BD-I) is an often chronic, debilitating condition in which medication is a mainstay of treatment. However, medication non adherence can negatively impact clinical outcomes, increasing the risk for relapse and (re)hospitalization. Long-acting injectables (LAIs), particularly relative to oral therapies, are an effective treatment option for BD-I that overcomes nonadherence, thereby promoting remission and functional recovery. However, despite their safety and efficacy, both clinician and patient factors impede their use in routine practice.
This CME Outfitters BriefCase utilizes a patient case to guide clinicians on best practices to engage patients in treatment planning for BD-I, including the feasibility of LAIs as an effective treatment option.
At the end of this CE activity, participants should be able to:
- Incorporate collaborative care discussions with patients with bipolar I disorder that include incorporating LAIs as a potential management option.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe ways to incorporate collaborative care discussions with patients with bipolar I disorder that include incorporating LAIs as a potential management option.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre reports that he receives grants/research support from The Canadian Institutes of Health Research (CIHR); Global Alliance for Chronic Diseases (GACD); National Natural Research Foundation of China; and Stanley Medical Research Institute. He is a consultant/on the speakers bureau for Allergan; Intra-Cellular Therapies INc.; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).